Clinical trialNACompleted
Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors
Role of Circulating Tumor Cells (CTC´s) Spread During Pancreaticoduodenectomy in Metastasis and Survival Rates in Patients With Pancreatic and Periampullary Tumors
- Outcome
- Finished, no results posted
- Phase
- NA
- Status
- Completed
- Study type
- Interventional
- Start
- 15 December 2017
- Expected end
- 15 July 2023
- Enrollment
- 86 participants
- Sites
- 1
- Primary outcomes
- Circulating tumor cells (CTC´s); Local tumor recurrence; Metastasis; Patient survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 14 May 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This multicentre, prospective and randomized study aims(1:1) to compare the rate of recurrence, metastasis and survival according to the levels of intraoperative circulating tumor cells (CTCs) during cephalic duodenopancreatectomy in patients with pancreatic and periampullary tumors.
Detailed description public domain (ClinicalTrials.gov)
Cephalic duodenopancreatectomy is the technique indicated for patients with pancreatic head carcinoma and periampullar tumors. There are different technical variants, it is not standardized what is the best option in relation to local recurrence, metastasis and survival. In the study, patients will be randomized into two study groups with pancreatic and periampullary tumors undergoing cephalic pancreatectomy (NT) vs initial approach by superior mesenteric artery (SMA). The measurement of circulating tumor cells (CTCs) allows to assess the degree of cellular dissemination due to surgical manipulation.CTCs will be evaluated during surgery (nº CTCs / mL blood). To do this, a maximum of 4 blood samples from the portal vein will be performed, in each study group according to the following scheme: * NT group: basal (at the beginning of surgery), portal vein pancreatic detachment, postresection (NT2) and before closure (NT3). * SMA group: basal (at the beginning of surgery), after Kocher maneuver and SMA dissection, postresection, before closure. Subsequently, the quantified levels of CTCs will be correlated with the occurrence of local tumor recurrence, metastasis development and patient patient survival.
Papers 7
- Builds on itEffects of the superior mesenteric artery approach versus the no-touch approach during pancreatoduodenectomy on the mob… DOI 10.1093/bjsopen/zrae123↗
- BackgroundCirculating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. DOI 10.1097/sla.0000000000001600↗
- BackgroundNo-touch isolation techniques for pancreatic cancer. DOI 10.1007/s00595-016-1317-5↗
- BackgroundCirculating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers … DOI 10.1186/s12885-015-1779-7↗
- BackgroundImproving outcomes in pancreatic cancer: key points in perioperative management. DOI 10.3748/wjg.v20.i39.14237↗
- BackgroundNo-touch pancreatectomy for invasive ductal carcinoma of the pancreas. DOI 10.6092/1590-8577/2502↗
- BackgroundReduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic… DOI 10.1001/jamasurg.2013.3643↗